Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PPIA | P62937 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3178001 | 0.89 | ABCB1 (0.52) | ABCB1NPC1HTTGAAPPIA | |
| SCHEMBL2463767 | 0.89 | ABCB1 (0.52) | ABCB1SGMS2NPC1MEN1KMT2A | |
| SCHEMBL7531833 | 0.87 | SGMS2 (0.58) | SGMS2NPC1HTTGAAPTGER1 | |
| SCHEMBL11339085 | 0.87 | HCRTR1 (0.58) | ABCB1NPC1GAAMEN1KMT2A | |
| SCHEMBL69725 | 0.86 | SGMS2 (0.52) | ABCB1SGMS2NPC1HTTGAA | |
| SCHEMBL30535266 | 0.86 | SGMS2 (0.52) | ABCB1SGMS2NPC1HTTGAA | |
| SCHEMBL3179257 | 0.85 | ABCB1 (0.52) | ABCB1NPC1HTTGAALMNA | |
| SCHEMBL3175398 | 0.83 | ABCB1 (0.48) | ABCB1NPC1GAAMEN1KMT2A | |
| SCHEMBL340937 | 0.82 | HTT (0.69) | SGMS2NPC1HTTPPIAPTGER1 | |
| SCHEMBL6243854 | 0.82 | NPC1 (0.64) | SGMS2NPC1HTTGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645772-B2 | 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-01-12 | — | — | US | claimed |
| US-20060035970-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2006-02-16 | — | — | US | claimed |
| EP-1556085-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004041165-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| EP-1310494-B1 | PPAR (delta) ACTIVATORS | NIPPON CHEMIPHAR CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| EP-1424330-B1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA | NIPPON CHEMIPHAR CO (JP) | 2011-09-28 | — | — | EP | disclosed |
| US-7652045-B2 | e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) | NIPPON CHEMIPHAR, CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7648999-B2 | Activator for peroxisome proliferator-activated receptor δ | NIPPON CHEMIPHAR CO., LTD. (JP) | 2010-01-19 | — | — | US | disclosed |
| US-7645772-B2 | 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090203908-A1 | Activator for Peroxisome Proliferator-Activated Receptor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1897872-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2008-03-12 | — | — | EP | disclosed |
| US-20080009631-A1 | Activator for peroxisome proliferator-activated receptor delta | SAKUMA SHOGO | 2008-01-10 | — | — | US | disclosed |
| EP-1556085-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050054674-A1 | Activator of peroxisome proliferator-activated receptor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| CN-1568316-A | Peroxisome proliferator-responsive receptor delta activators | NIPPON CHEMIPHAR CO (JP) | 2005-01-19 | — | — | CN | disclosed |
| US-6787552-B2 | HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| EP-1424330-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2004041165-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097739-A1 | Ppar delta activators | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1310494-A1 | PPAR (delta) ACTIVATORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009631-A1 | Activator for peroxisome proliferator-activated receptor delta | PPARG, PPARD, PPARA | ABCB1 4438/4885SGMS2 1022/4885NPC1 2025/4885 |
| US-20040097739-A1 | Ppar delta activators | PPARD, PPARG, PPARA | ABCB1 4009/4885SGMS2 896/4885NPC1 920/4885 |
| US-20090203908-A1 | Activator for Peroxisome Proliferator-Activated Receptor | PPARA, PPARG, PPARD | ABCB1 4505/4885SGMS2 447/4885NPC1 1806/4885 |
| US-20050054674-A1 | Activator of peroxisome proliferator-activated receptor | PPARG, PPARD, PPARA | ABCB1 4327/4885SGMS2 1056/4885NPC1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.